Jun 21, 2024 15:35 JST

Source: Eisai

Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City

Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024.

This project is a dementia examination program targeting approximately 12,300 Bunkyo City residents between the ages of 55 and 75, at a milestone of every 5 years. Brain health is checked using “NouKNOW” (pronounced “NOH-NOH”), a digital tool for self-assessment of cognitive function, and based on the assessment results as well as a medical interview, physicians will provide medical advice or referrals to medical institutions. The project also introduces support available from visiting nurses, and encourages participation in lifestyle improvement programs. Since early detection and response to dementia is important, Tokyo is recommending that the target age group for dementia examination be expanded from the current age of 70 and over to 50 and over. This project, which targets 55-year-olds, is one of the pioneering examples of local government efforts toward the early detection of dementia.

The dementia examination project has been implemented since FY2021 as a priority policy of Bunkyo City, and Eisai has been commissioned for the project since it’s launch, providing NouKNOW and operational support for their public examinations. In FY2022, a Pay For Success (PFS) contract was introduced and targets were established for the outcome indicators of number of NouKNOW checks performed and number of participants in lifestyle improvement programs. Eisai achieved both outcome indicators in FY2022 and FY2023 through measures such as holding NouKNOW trial sessions and providing opportunities to experience "Brepacise®," an exercise program developed by Eisai.

In FY2023, 245 people participated in on-site examinations, of which approximately 12% led to recommendations to see a medical institution. In a survey conducted after the examination, 52% of the 122 respondents said that they had developed a more positive outlook on dementia, and 68% said that they had become more interested in the brain and health.         

Eisai has concluded regional cooperation agreements with local governments, medical associations, and other organizations throughout Japan, providing opportunities for brain health assessments tailored to local issues and conducting initiatives to establish a pathway to subsequent medical care and support. In FY2023, these initiatives were promoted in 60 local governments. Moving forward, Eisai will continue to contribute to the creation of a community where local residents are aware of and check their brain health from the stage where they are in a healthy condition, and where early detection, diagnosis, and preparation for dementia are possible, aiming to realize a Dementia-Inclusive Society where people with dementia can live their lives how they would like.

About NouKNOW

NouKNOW (non-medical device) is a tool that uses a simple card test using a PC, tablet or smartphone device to perform tests evaluating psychomotor function, attention, learning and memory, and working memory. This digital tool allows users to self-assess independently and in a short time frame (approx.15 minutes), enabling regular assessments in instances such as daily life and health checkups. It has been adopted by a number of medical and research institutions, local governments, corporations and universities.

For additional information, please visit https://nouknow.jp/. (Japanese only)

(List of partners: https://nouknow.jp/partner/)

About Pay For Success (PFS)

Pay For Success (PFS) is a new method of public-private partnership to set outcome indicators in accordance with the administrative issues to be solved by the projects that local public entities, etc. contract out to private sectors for its implementation, and the amount paid by the local public entity, etc. to the private sector for outsourcing a project is linked to improvement of the relevant outcome indicators as evaluated by a third party. PFS is a policy promoted by the Cabinet Office of Japan, which is expected to improve the quality of public services and reduce expenditures.

About Brepacise

Brepacise is a dual-task exercise program that stimulates the body and brain by moving the arms and legs to music while also incorporating intellectual challenges. Eisai developed this product with the review of a physician as an easy and fun introductory exercise for those concerned about their brain health. It is being used in health classes and online events run by local governments.

For additional information, please visit the dementia information site “Sodan e-65” operated by Theoria technologies Inc., a member of Eisai Group. (https://soudan-e65.com/maintenance/brain_exercise/, Japanese only)

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120  

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 12 2024 11:56 JST
 
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
July 11 2024 09:00 JST
 
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
July 02 2024 12:01 JST
 
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
June 28 2024 14:57 JST
 
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
June 10 2024 17:50 JST
 
Eisai Named to List of The Time 100 Most Influential Companies
June 03 2024 16:08 JST
 
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
June 03 2024 14:22 JST
 
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
May 28 2024 14:19 JST
 
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
May 23 2024 17:07 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
May 22 2024 11:55 JST
 
More Press release >>

Latest Press Release


More Latest Release >>